-
NUMBER OF INSIDER BUYING
(Last 12 Months)
1 -
NUMBER OF INSIDER SELLING
(Last 12 Months)
5 -
AMOUNT OF INSIDERS BUYING
(Last 12 Months)
$8.93 M -
AMOUNT OF INSIDERS SELLING
(Last 12 Months)
$5.37 M
KalVista Pharmaceuticals, Inc. Insider Transactions
KalVista Pharmaceuticals, Inc. Insider Trades History
| Insider Name | Buy/Sell | Shares Bought/Sold @ Price |
Total Transaction | Shares Held After Transaction |
Transaction Date | Filing Date | Details |
|---|---|---|---|---|---|---|---|
|
Palleiko Benjamin L
Director, CHIEF EXECUTIVE OFFICER |
Sell | 7,465 @ $11.53 | $86,068 | 224,547 | 06/07/2024 | 06/10/2024 | |
|
Yea Christopher
CHIEF DEVELOPMENT OFFICER |
Sell | 11,610 @ $11.76 | $136,586 | 80,074 | 05/20/2024 | 05/21/2024 | |
|
Palleiko Benjamin L
Director, CHIEF EXECUTIVE OFFICER |
Sell | 21,959 @ $11.76 | $258,337 | 216,387 | 05/20/2024 | 05/21/2024 | |
|
Feener Edward P.
CHIEF SCIENTIFIC OFFICER |
Sell | 8,088 @ $11.76 | $95,151 | 72,858 | 05/20/2024 | 05/21/2024 | |
|
Audhya Paul K.
CHIEF MEDICAL OFFICER |
Sell | 13,175 @ $11.76 | $154,997 | 70,325 | 05/20/2024 | 05/21/2024 | |
|
Venrock Healthcare Capital Partners III, L.P.
10 percent owner |
Buy | 655,738 @ $0.00 | $656 | 655,738 | 02/20/2024 | 02/22/2024 | |
|
Feener Edward P.
CHIEF SCIENTIFIC OFFICER |
Sell | 8,397 @ $14.11 | $118,522 | 82,048 | 02/20/2024 | 02/21/2024 | |
|
Feener Edward P.
CHIEF SCIENTIFIC OFFICER |
Sell | 19,591 @ $14.04 | $274,991 | 62,457 | 02/20/2024 | 02/21/2024 | |
|
Feener Edward P.
CHIEF SCIENTIFIC OFFICER |
Sell | 300 @ $14.72 | $4,416 | 62,157 | 02/20/2024 | 02/21/2024 | |
|
Yea Christopher
CHIEF DEVELOPMENT OFFICER |
Sell | 12,053 @ $14.11 | $170,124 | 72,895 | 02/20/2024 | 02/21/2024 | |
|
Palleiko Benjamin L
CFO, CBO |
Sell | 22,802 @ $14.11 | $321,846 | 187,315 | 02/20/2024 | 02/21/2024 | |
|
Audhya Paul K.
CHIEF MEDICAL OFFICER |
Sell | 14,295 @ $14.12 | $201,774 | 52,886 | 02/20/2024 | 02/21/2024 | |
| Sell | 24,888 @ $14.11 | $351,289 | 211,203 | 02/20/2024 | 02/21/2024 | ||
|
Palleiko Benjamin L
CFO, CBO |
Sell | 40,855 @ $15.01 | $613,205 | 159,088 | 02/14/2024 | 02/16/2024 | |
| Sell | 58,356 @ $15.01 | $875,883 | 181,676 | 02/14/2024 | 02/16/2024 | ||
|
Feener Edward P.
CHIEF SCIENTIFIC OFFICER |
Sell | 28,171 @ $15.01 | $422,827 | 71,657 | 02/14/2024 | 02/16/2024 | |
|
Yea Christopher
CHIEF DEVELOPMENT OFFICER |
Sell | 39,886 @ $15.01 | $598,661 | 66,160 | 02/14/2024 | 02/16/2024 | |
|
Venrock Healthcare Capital Partners III, L.P.
10 percent owner |
Buy | 29,747 @ $14.70 | $437,281 | 4,824,731 | 02/08/2024 | 02/08/2024 | |
|
Venrock Healthcare Capital Partners III, L.P.
10 percent owner |
Buy | 51,827 @ $14.56 | $754,601 | 4,794,984 | 02/07/2024 | 02/08/2024 | |
|
Venrock Healthcare Capital Partners III, L.P.
10 percent owner |
Buy | 4,474 @ $14.74 | $65,947 | 4,743,157 | 02/06/2024 | 02/08/2024 |
KalVista Pharmaceuticals, Inc. Frequently Asked Questions
-
Who is on KalVista Pharmaceuticals, Inc.'s Insider Roster?
The list of insiders at KalVista Pharmaceuticals, Inc. includes Feener Edward P., Venrock Healthcare Capital Partners III, L.P., Crockett Thomas Andrew, Yea Christopher, Palleiko Benjamin L, Audhya Paul K..
-
How much insider selling is happening at KalVista Pharmaceuticals, Inc.?
Insiders have sold a total of 381,791 KalVista Pharmaceuticals, Inc. shares in the last 12 months for a total of 5.37 M sold.
-
Which KalVista Pharmaceuticals, Inc. insiders have been selling company stock?
The following insiders have sold KalVista Pharmaceuticals, Inc. shares in the last 12 months: Feener Edward P. ($1.44 M), Crockett Thomas Andrew ($1.39 M), Yea Christopher ($905,371), Palleiko Benjamin L ($1.28 M), Audhya Paul K. ($356,771),
-
How much insider buying is happening at KalVista Pharmaceuticals, Inc.?
Insiders have purchased a total of 1.33 M KalVista Pharmaceuticals, Inc. shares in the last 12 months for a total of 8.93 M sold.
-
Which KalVista Pharmaceuticals, Inc. insiders have been buying company stock?
The following insiders have purchased KalVista Pharmaceuticals, Inc. shares in the last 12 months: Venrock Healthcare Capital Partners III, L.P. ($8.93 M),